Responses
Original Article
Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study
Compose a Response to This Article
Other responses
No responses have been published for this article.